DOV-216,303
| |
Legal status | |
---|---|
Legal status | |
Identifiers | |
| |
CAS Number | |
PubChem CID | |
ChemSpider | |
ChEMBL | |
Chemical and physical data | |
Formula | C11H11Cl2N |
Molar mass | 228.117 g/mol |
3D model (JSmol) | |
| |
| |
|
DOV 216,303 is an antidepressant drug originally developed by DOV Pharmaceutical and was licensed to Merck & Co. in 2004;[1] Merck and Dov terminated their relationship in December 2006.[2]:12[3]
It is a triple reuptake inhibitor (TRI), or serotonin-norepinephrine-dopamine reuptake inhibitor (SNDRI).[4] It is the racemic mixture of amitifadine (DOV-21,947) and its (–)-enantiomer, DOV-102,677. Its IC50 values for SERT, NET, and DAT are Ki 14 nM, 20 nM, and 78 nM, respectively.[4]
As of March 2008, Dov had no intention to further develop DOV-216,303 because the patent on the compound had expired.[2]:6
See also
References
- ↑ McCoy, Michael (August 12, 2004). "Merck and DOV Pharmaceutical In Drug Pact". C&EN.
- 1 2 "10-K For the fiscal year ended December 31, 2007". Dov Pharmaceutical via SEC Edgar. March 31, 2008.
DOV 216,303 was originally in development for depression; however as the patented composition of matter claim has expired, there are no ongoing clinical trials of DOV 216,303 and none are planned.
- ↑ "DOV 216303". AdisInsight. Retrieved 26 February 2017.
- 1 2 Skolnick, P.; Krieter, P.; Tizzano, J.; Basile, A.; Popik, P.; Czobor, P.; Lippa, A. (2006). "Preclinical and Clinical Pharmacology of DOV 216,303, a "Triple" Reuptake Inhibitor". CNS Drug Reviews. 12 (2): 123–134. doi:10.1111/j.1527-3458.2006.00123.x. PMID 16958986.
This article is issued from
Wikipedia.
The text is licensed under Creative Commons - Attribution - Sharealike.
Additional terms may apply for the media files.